

# Chel Hun Choi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2490361/publications.pdf>

Version: 2024-02-01

134  
papers

3,628  
citations

236925

25  
h-index

155660

55  
g-index

137  
all docs

137  
docs citations

137  
times ranked

5472  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival. <i>Cancer Research and Treatment</i> , 2022, 54, 245-252.	3.0	5
2	Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 93-100.	2.5	36
3	Utility of 3T MRI in Women with IB1 Cervical Cancer in Determining the Necessity of Less Invasive Surgery. <i>Cancers</i> , 2022, 14, 224.	3.7	3
4	Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	21
5	Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. <i>Gynecologic Oncology</i> , 2022, , .	1.4	2
6	Safety and efficacy study of laparoscopic or robotic radical surgery using an endoscopic stapler for inhibiting tumour spillage of cervical malignant neoplasms evaluating survival (SOLUTION): a multi-centre, open-label, single-arm, phase II trial protocol. <i>BMC Cancer</i> , 2022, 22, 331.	2.6	9
7	Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach. <i>Gynecologic Oncology</i> , 2022, 164, 535-542.	1.4	19
8	Clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2022, 61, 333-338.	1.3	3
9	Prognostic Significance of HER3 Expression in Patients with Cervical Cancer. <i>Cancers</i> , 2022, 14, 2139.	3.7	3
10	A multicenter phase II randomized trial of durvalumab (D) versus physician's choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5565-5565.	1.6	7
11	Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in <i>BRCA </i>non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/OPEB-01.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17579-e17579.	1.6	1
12	Vulvar epithelioid sarcoma: A case report with literature review. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2021, 60, 132-135.	1.3	8
13	Discrepancy between Cytology and Histology in Cervical Cancer Screening: a Multicenter Retrospective Study (KGOG 1040). <i>Journal of Korean Medical Science</i> , 2021, 36, e164.	2.5	6
14	Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e72.	2.2	3
15	Minimally-Invasive Versus Abdominal Hysterectomy for Endometrial Carcinoma With Glandular or Stromal Invasion of Cervix. <i>Frontiers in Oncology</i> , 2021, 11, 670214.	2.8	2
16	An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5520-5520.	1.6	2
17	Phase IIa study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5512-5512.	1.6	2
18	Metabolic syndrome and persistent cervical human papillomavirus infection. <i>Gynecologic Oncology</i> , 2021, 161, 559-564.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Single-port access (SPA) laparoscopic myomectomy with uterine artery ligation via a retroperitoneal approach is feasible in women with large uterine leiomyoma. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2021, 60, 752-757.	1.3	1
20	Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 803-812.	3.0	2
21	Validation of Potential Protein Markers Predicting Chemoradioresistance in Early Cervical Cancer by Immunohistochemistry. <i>Frontiers in Oncology</i> , 2021, 11, 665595.	2.8	2
22	Machine Learning Models to Predict Survival Outcomes According to the Surgical Approach of Primary Radical Hysterectomy in Patients with Early Cervical Cancer. <i>Cancers</i> , 2021, 13, 3709.	3.7	8
23	A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in <i>BRCA</i> non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). <i>Journal of Gynecologic Oncology</i> , 2021, 32, e31.	2.2	17
24	Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. <i>Cancer Science</i> , 2021, 112, 5055-5067.	3.9	6
25	Comparative performance of various human papillomavirus assays available in Korea for detecting cervical intraepithelial neoplasia. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, , .	1.3	1
26	Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 770103.	2.8	2
27	Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer. <i>Journal of Ovarian Research</i> , 2020, 13, 1.	3.0	31
28	CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 211-221.	1.4	15
29	Feasibility of Single-Port Access (SPA) Laparoscopy for Large Ovarian Tumor Suspected to Be Borderline Ovarian Tumor. <i>Frontiers in Oncology</i> , 2020, 10, 583515.	2.8	4
30	Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type. <i>Journal of Clinical Medicine</i> , 2020, 9, 3471.	2.4	8
31	The Prognostic Model of Pre-Treatment Complete Blood Count (CBC) for Recurrence in Early Cervical Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 2960.	2.4	2
32	Prognostic significance of USP10 and p14ARF expression in patients with colorectal cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152988.	2.3	17
33	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1239-1242.	2.5	14
34	Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2020, 157, 437-443.	1.4	17
35	Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer. <i>Current Problems in Cancer</i> , 2020, 44, 100557.	2.0	5
36	Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 147.	2.4	14

#	ARTICLE	IF	CITATIONS
37	Comparison of Laparoscopy and Laparotomy for Para-Aortic Lymphadenectomy in Women With Presumed Stage II High-Risk Endometrial Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 451.	2.8	4
38	Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1137.	2.4	2
39	Prognostic Model for Survival and Recurrence in Patients with Early-Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028). <i>Cancer Research and Treatment</i> , 2020, 52, 320-333.	3.0	19
40	Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status. <i>Cancer Research and Treatment</i> , 2020, 52, 516-523.	3.0	9
41	Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients. <i>Cancer Research and Treatment</i> , 2020, 52, 645-654.	3.0	13
42	Long-term outcomes of single-port laparoscopic myomectomy using a modified suture technique. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 164-172.	1.6	5
43	Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. <i>Yonsei Medical Journal</i> , 2020, 61, 935.	2.2	0
44	Combination of a pulmonary recruitment maneuver and intraperitoneal bupivacaine for the reduction of postoperative shoulder pain in gynecologic laparoscopy: a randomized, controlled trial. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 187-194.	1.6	6
45	Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028). <i>Gynecologic Oncology</i> , 2019, 154, 547-553.	1.4	68
46	An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 789-792.	1.3	17
47	Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1920.	2.4	8
48	Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer. <i>Scientific Reports</i> , 2019, 9, 15394.	3.3	27
49	Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e11.	2.2	8
50	Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases. <i>Obstetrics and Gynecology Science</i> , 2019, 62, 103.	1.6	5
51	Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy. <i>European Radiology</i> , 2019, 29, 6236-6244.	4.5	19
52	Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e65.	2.2	38
53	Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 46, 337-346.	1.3	4
54	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. <i>Genome Biology</i> , 2019, 20, 253.	8.8	16

#	ARTICLE	IF	CITATIONS
55	A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e112.	2.2	15
56	Comparison between laparoendoscopic single-site and conventional laparoscopic surgery in mature cystic teratoma of the ovary. <i>Gynecology and Minimally Invasive Therapy</i> , 2019, 8, 155.	0.9	10
57	Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea. <i>Obstetrics and Gynecology Science</i> , 2019, 62, 411.	1.6	7
58	Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 112-118.	3.0	4
59	Effect of postoperative adjuvant treatment in the therapeutic management of stage I, morcellated uterine leiomyosarcoma: A Korean multicenter study. <i>Journal of Clinical Oncology</i> , 2019, 37, e17106-e17106.	1.6	0
60	Ubiquitylation and degradation of adenomatous polyposis coli by MKRN1 enhances Wnt/ $\beta$ 2-catenin signaling. <i>Oncogene</i> , 2018, 37, 4273-4286.	5.9	20
61	Genomic Network-Based Analysis Reveals Pancreatic Adenocarcinoma Up-Regulating Factor-Related Prognostic Markers in Cervical Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 465.	2.8	6
62	Clinical characteristics and outcomes of placental site trophoblastic tumor: experience of single institution in Korea. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 319.	1.6	8
63	Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 352.	1.6	4
64	Dual loss of USP10 and p14ARF protein expression is associated with poor prognosis in patients with small intestinal adenocarcinoma. <i>Tumor Biology</i> , 2018, 40, 101042831880867.	1.8	10
65	Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e13.	2.2	9
66	The role of appendectomy in patients with mucinous borderline ovarian tumors. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 229, 112-116.	1.1	10
67	Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e18.	2.2	29
68	Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 461-473.	3.0	3
69	Minimally invasive compared with open surgery in patients with borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2017, 145, 508-512.	1.4	21
70	Effective thermal destruction of residual tubal epithelium using an advanced sealing device in opportunistic salpingectomy: A randomized trial. <i>Gynecology and Minimally Invasive Therapy</i> , 2017, 6, 108-112.	0.9	0
71	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
72	The anti-cancer effects of itraconazole in epithelial ovarian cancer. <i>Scientific Reports</i> , 2017, 7, 6552.	3.3	37

#	ARTICLE	IF	CITATIONS
73	Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 170.	1.6	33
74	Laparoendoscopic single-site radical hysterectomy for early stage cervical cancer. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 110.	1.6	3
75	Extrauterine epithelioid trophoblastic tumor in hysterectomized woman. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 124.	1.6	18
76	Surgical manual of the Korean Gynecologic Oncology Group: classification of hysterectomy and lymphadenectomy. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e5.	2.2	13
77	Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 595-606.	3.0	24
78	Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 635-642.	3.0	10
79	Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. <i>Cancer Research and Treatment</i> , 2017, 49, 915-926.	3.0	58
80	Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e46.	2.2	9
81	Retroperitoneal Approach in Single-Port Laparoscopic Hysterectomy. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2016, 20, e2016.00001.	1.1	4
82	Long-term outcomes of magnetic resonance imaging-invisible endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e38.	2.2	8
83	Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e24.	2.2	6
84	c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. <i>Scientific Reports</i> , 2016, 6, 38502.	3.3	34
85	Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. <i>Gynecologic Oncology</i> , 2016, 143, 252-257.	1.4	20
86	Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2016, 56, 639-647.	1.0	14
87	Women with double primary cancers of the colorectum and endometrium: do they have Lynch syndrome?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 199, 208-212.	1.1	4
88	Uterine Fibroids: Correlation of T2 Signal Intensity with Semiquantitative Perfusion MR Parameters in Patients Screened for MR-guided High-Intensity Focused Ultrasound Ablation. <i>Radiology</i> , 2016, 278, 925-935.	7.3	17
89	Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 77052-77070.	1.8	17
90	Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells. <i>Anticancer Research</i> , 2016, 36, 6381-6388.	1.1	13

#	ARTICLE	IF	CITATIONS
91	Prognostic model for disease-free survival, lymphatic and/or hematogenous recurrence, in patients with early stage cervical cancer treated with radical hysterectomy: A Korean Gynecologic Oncology Group Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17000-e17000.	1.6	0
92	Single-site robotic surgery in gynecologic cancer: a pilot study. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 62.	2.2	19
93	Robotic high para-aortic lymph node dissection with high port placement using same port for pelvic surgery in gynecologic cancer patients. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 222.	2.2	2
94	Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification. <i>Obstetrics and Gynecology Science</i> , 2015, 58, 124.	1.6	45
95	Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. <i>Oncotarget</i> , 2015, 6, 35040-35050.	1.8	48
96	The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 190, 26-30.	1.1	5
97	Perioperative Outcomes of Radical Trachelectomy in Early-Stage Cervical Cancer: Vaginal Versus Laparoscopic Approaches. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1051-1057.	2.5	16
98	Pancreatic adenocarcinoma up-regulated factor expression is associated with disease-specific survival in cervical cancer patients. <i>Human Pathology</i> , 2015, 46, 884-893.	2.0	17
99	Borderline ovarian tumor in women aged ≥65 years: impact on recurrence and survival. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 184, 38-42.	1.1	11
100	A prospective comparative study of cosmetic satisfaction for three different surgical approaches. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 190, 48-51.	1.1	6
101	Is laparoendoscopic single-site surgery (LESS) retroperitoneal hysterectomy feasible?: Surgical outcomes of the initial 27 cases. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2015, 54, 150-154.	1.3	4
102	Analysis of clinical outcomes of patients with adenoid cystic carcinoma of Bartholin glands. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5688-94.	0.5	10
103	Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 28.	1.6	27
104	Primary ovarian choriocarcinoma mimicking ectopic pregnancy. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 330.	1.6	19
105	Tumor Suppressive Effects of Bromodomain-Containing Protein 7 (BRD7) in Epithelial Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 565-575.	7.0	56
106	Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 108-117.	1.4	29
107	Robotic Versus Laparoscopic Radical Hysterectomy in Cervical Cancer Patients: A Matched-Case Comparative Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1466-1473.	2.5	34
108	Postoperative outcomes of MR-invisible stage IB1 cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 168.e1-168.e7.	1.3	16

#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin. <i>Supportive Care in Cancer</i> , 2014, 22, 1181-1187.	2.2	15
110	Laparoendoscopic single-site (LESS) myomectomy: characteristics of the appropriate myoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 175, 58-61.	1.1	15
111	Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2014, 53, 343-347.	1.3	19
112	Meta-analysis of the effects of beta blocker on survival time in cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1179-1188.	2.5	72
113	Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: A multicenter review of 114 cases. <i>Gynecologic Oncology</i> , 2014, 132, 70-75.	1.4	63
114	Surgical Outcomes of a New Approach to Laparoscopic Myomectomy: Single-Port and Modified Suture Technique. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 580-585.	0.6	31
115	Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. <i>Human Pathology</i> , 2013, 44, 1017-1023.	2.0	17
116	Comparison of Laparoscopic-Assisted Radical Vaginal Hysterectomy and Laparoscopic Radical Hysterectomy in the Treatment of Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 3839-3848.	1.5	31
117	Angiotensin II type I receptor and miR-155 in endometrial cancers: Synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. <i>Gynecologic Oncology</i> , 2012, 126, 124-131.	1.4	36
118	Superior vena cava syndrome secondary to hickman catheter in the advanced cervical cancer patient treated with concurrent chemoradiotherapy: A case report. <i>Korean Journal of Obstetrics &amp; Gynecology</i> , 2012, 55, 761.	0.1	0
119	A Matched-Case Comparison to Explore the Role of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1252-1257.	0.8	38
120	Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 463-469.	2.5	23
121	Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. <i>Cancer</i> , 2011, 117, 2104-2111.	4.1	14
122	Peritoneal Tuberculosis: A Retrospective Review of 20 Cases and Comparison With Primary Peritoneal Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 798-803.	2.5	25
123	Prognostic significance of pSTAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2010, 36, 304-310.	1.3	11
124	Clinical significance of pmTOR expression in endometrioid endometrial carcinoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 153, 207-210.	1.1	9
125	The prognostic significance of the SUVmax (maximum standardized uptake value for F-18) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 results. <i>Gynecologic Oncology</i> , 2009, 115, 65-68.	1.4	78
126	Single-Port Access Laparoscopic-Assisted Vaginal Hysterectomy: A Novel Method with a Wound Retractor and a Glove. <i>Journal of Minimally Invasive Gynecology</i> , 2009, 16, 450-453.	0.6	126



#	ARTICLE	IF	CITATIONS
127	Prognostic Value of Baseline Lymphocyte Count in Cervical Carcinoma Treated With Concurrent Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 199-204.	0.8	30
128	Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2008, 8, 295.	2.6	22
129	Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. <i>Cancer Letters</i> , 2007, 255, 26-33.	7.2	51
130	Phase II Study of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer: Preliminary Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 817-822.	0.8	23
131	Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2â€“IIB cervical carcinoma. <i>Gynecologic Oncology</i> , 2007, 104, 64-69.	1.4	35
132	Papillary serous carcinoma in ovaries of normal size: A clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2007, 105, 762-768.	1.4	28
133	Expression of CD44 adhesion molecules on human placentae. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 128, 243-247.	1.1	8
134	Neoadjuvant chemotherapy with mitomycin-C, vincristine and cisplatin (MVC) for patients with loco-regionally advanced cervical carcinoma. <i>Korean Journal of Gynecologic Oncology</i> , 2006, 17, 15.	0.1	0